Lv6
2670 积分 2024-02-08 加入
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2024 update on the diagnosis, risk‐stratification, and management
1个月前
已完结
Primary Large B-cell Lymphomas of Immune-Privileged Sites
3个月前
已完结
Primary Large B-cell Lymphomas of Immune-Privileged Sites
3个月前
已关闭
Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma
3个月前
已完结
The efficacy and safety of anlotinib plus PD-1 inhibitor in locally advanced/metastatic esophageal squamous cell carcinoma (ESCC) patients who progressed on prior immune checkpoint inhibitors (ICIs): a retrospective real-world study (NCT 04984096)
3个月前
已完结
Primary central nervous system lymphoma
3个月前
已完结
Correction: SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma
4个月前
已完结
Novel pharmacotherapies for the treatment of liposarcoma: a comprehensive update
4个月前
已完结
Rituximab, used alone or in combination, is superior to other treatment modalities in splenic marginal zone lymphoma
4个月前
已完结
Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study
4个月前
已完结
皖公网安备34019202002308
